

Certificate of Analysis

47 W Polk St. STE 100-241 Chicago, IL 60605 liftmode@liftmode.com

Lift \\ode

Yohimbine

Pausinystalia Yohimbe Bark Extract

Material Lot #: 20211025 Test Date: 02-22-2022

Country of Origin: China Re-Test Date: 01-19-2025

> Analysis Claim Result Yohimbine ≥98% 99.9%

Test	Specification	Result
Yohimbine (HPLC)	≥98%	%99.9
Lead Mercury Cadmium Arsenic	≤0.5ppm ≤0.5ppm ≤0.5ppm ≤0.5 ppm	0.00961 ppm <0.005 ppm <0.005 ppm <0.01 ppm
Yeast Moulds Escherichia coli Coliforms Salmonella Staphylococcus aureus	<1000 cfu/g <100 cfu/g <100 cfu/g <10 cfu/g <10 cfu/g Negative <10 cfu/g	<10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g <10 cfu/g Negative <10 cfu/g

Yohimbine should be stored at or below room temperature in a tightly sealed durable container. Yohimbine should be protected from excess heat, direct sunlight, excess humidity, and moisture. Yohimbine has a retesting period of 3 years from the date of analysis when properly stored.



Main Benefits

- Yohimbine is an indole alkaloid that is extracted from the Yohimbe tree in Central Africa.
- •It has long been used as a potent energizing, libido-en-Yohimbine temporarily inhibits the reuptake of norepinephrine, producing noticeable energizing and cognitive effects.
- · Anecdotally, it is said to have energizing effects while supporting healthy vitality.

Main Cautions

- · Yohimbine HCl can cause rapid or racing heart rate, increased blood pressure, nausea, dizziness, anxiety, headache, and irritability, at normal serving sizes.
- · Overstimulation is very unpleasant and the negative experience of exceeding the serving size will be more noticeable than any benefits. **DO NOT EXCEED 8 mg per** serving or 16 mg per day.
- · Consult your physician before using Yohimbine if you are taking any medication. Yohimbine has not been tested for safety in pregnant or breastfeeding women

Usage Tips

- · A micro transfer measuring scoop is included. One rounded scoop contains approximately one serving, or approximately **4mg of Yohimbine.** As a dietary supplement, take 1-4 servings up to 3 times per day, (optimally, 1hour prior to activity). Please start with the lowest suggested quantity to assess response.
- The negative effects of Yohimbine are dependent on the amount taken, so use of a scale with 1mg/0.001g accuracy is required.
- · Use of capsules, or mixing with tea, yogurt, apple sauce, or oatmeal may help make the powder more
- This supplement is not intended to treat, diagnose, prevent, or cure any diseases. Consult your healthcare provider before use, if you have a medical condition, or if you are taking any prescription medications. Do not use Yohimbine if you are taking CNS stimulants, MAOIs, blood pressure medication, alpha blockers, beta blockers, asthma or allergy medications.
- It is safe to stack Yohimbine with other non-stimulanting supplements, so long as the amount consumed does not exceed the suggested serving
- The benefits of Yohimbine are most effective when they are supported by a healthy diet and plenty of



425 BARCLAY BOULEVARD Lincolnshire, IL 60069

eurofins | Eurofins Microbiology Laboratories (New Berlin)

Eurofins Microbiology Laboratories (New Berlin)

2345 S. 170th St. New Berlin, Wisconsin 53151 +1 262 754 5300 Micro-MKE@EurofinsUS.com

Synaptent Joseph Watkins

ANALYTICAL REPORT

Client Code: QH0000902 PO#: 20220125

AR-22-QH-006120-01

Received On: 28Jan2022 Reported On: 02Feb2022

Eurofins Sample Code: 477-2022-01280227 Sample Registration Date: 28Jan2022 Condition Upon Receipt: acceptable, 17.5°C Client Sample Code: 20211025 Sample Description: YOHIMBINE Sample Reference Reference AOAC 2011.19 and 993.14 (modified) Accreditation ISO/IEC 17025:2017 A2LA 2918.01 FS001 - Heavy Metals (As, Cd, Hg, and Pb) Completed 02Feb2022 Parameter Result <10.0 ppb <5.00 ppb Cadmium 9.61 ppb Lead <5.00 ppb Accreditation ISO/IEC 17025:2017 A2LA 3329.07 UM8VD - Total Coliforms - CMMEF Chapter 9.933 Reference CMMEF Chapter 9,933 Completed 29Jan2022

Parameter Result < 10 cfu/g

Result Parameter Escherichia coli < 10 cfu/g

UMDTC - Salmonella species - AOAC-RI Reference AOAC-RI 121501 Accreditation ISO/IEC 17025:2017 Completed 29Jan2022 A2LA 3329.07

Paramete Not Detected per 25 g Salmonella

Accreditation ISO/IEC 17025:2017 A2LA 3329.07 UMHBM - Staphylococcus aureus - BAM Reference BAM Chapter 12 Chapter 12

Parameter Staphylococcus aureus Result < 10 cfu/g

> Page 1 of 2 2/2/22 10:19 pm



S & N LABS

2021 F. Fourth Street Santa Ana California 92705 (714) 543-2211

2 February 2022

	Job Number:	25702b	
ı	PO Number:	verbal	

Synaptent LLC 47 W. Polk Street #100-241 Chicago, Illinois 60605

REPORT OF ANALYSIS

One small jar labeled "Yohimbine #20211025" was received on 31 January 2022. The contents of the jar were analyzed for purity using high pressure liquid chromatography (HPLC). The detector was set to 220nm. The results are summarized in the table below.

Sample	Chromatographic Purity (% area)			
Yohimbine #20211025	99.9			

Nuf & Sprigram Neil E. Spingam, Ph.D.

Synaptent Joseph Watkins

ANALYTICAL REPORT 425 BARCLAY BOULEVARD Lincolnshire, IL 60069

AR-22-QH-006120-01

Client Code: QH0000902 PO#: 20220125

Received On: 28Jan2022 Reported On: 02Feb2022

Eurofins Sample Code: 477-2022-01280227 Sample Registration Date: 28Jan2022 Client Sample Code: 20211025 Condition Upon Receipt: acceptable, 17.5°C

Sample Description: YOHIMBINE Sample Reference:

UMIB1 - Yeast - FDA BAM Chapter 18 Reference FDA BAM Chapter 18 mod. Completed 02Feb2022

Parameter Yeast Result < 10 cfu/g

Reference CMMEF Chapter 8.72 Accreditation ISO/IEC 17025:2017 A2LA 3329.07 UMVSE - Aerobic Plate Count - CMMEF Chapter 8.72 Completed 30Jan2022

Parameter Result Aerobic Plate Count < 10 cfu/a

Subcontracting partners: 1 - Eurofins Food Chemistry Testing US Madison, WI

Respectfully Submitted.



CM Juinn Christine Gwinn Associate Technical Leader

Results shown in this report relate solely to the item submitted for analysis. I Any opinions/interpretations expressed on this report are given independent of the laboratory's scope of accreditation. I All results are reported on an "As Received" basis unless otherwise stated. I Reports shall not be reproduced except in full without written permission of Eurofins Scientific, Inc. I All work done in accordance with Eurofins General Terms and Conditions of Sale:
www.eurofinsus.com/terms and conditions.pdf | Vinicates a subcontract test to a different lab. Lable) are listed at end of the report. For further details about the performing labs please contact your customer service contact at Eurofins, Measurement of uncertainty can be obtained upon request.


Page 2 of 2

2/2/22 10:19 pm

Instrument:Annex-2 Sequence:25702-Bromantane and Yohimbine Purities

Page 1 of 1

Chromatogram and Results					
Injection Details					
Injection Name:	Yohimbine 20211025	Run Time (min):	25.00		
Vial Number:	GE3	Injection Volume:	10.00		
Injection Type:	Unknown	Channel:	EXT220NM		
Calibration Level:		Wavelength:	n.a.		
Instrument Method:	AD 250mm Prodigy 25min Purity Method	Bandwidth:	n.a.		
Processing Method:	Processing Method	Dilution Factor:	1.0000		
Injection Date/Time:	02/Feb/22 13:26	Sample Weight:	1.0000		



Integration Results								
No.	Peak Name	Retention Time min	Area mAU*min	Height mAU	Relative Area %	Relative Height %	Amount	
1 2 3	Yohimbine	9.153 9.343 9.583	0.012 0.003 89.240	0.139 0.000 1020.288	0.01 0.00 99.86	0.01 0.00 99.91	n.a. n.a. n.a.	
4 Tota	d:	10.173	0.112	0.763	0.13	0.07	n.a.	